To the Editor A recent study published by Wang et al1 evaluated POLE/POLD1 variants as potential biomarkers for immune checkpoint inhibitor (ICI) treatment outcomes in multiple cancer types using the cBioPortal database (https://www.cbioportal.org). The authors conclude that “mutations in all exons of these 2 genes should be integrated into predictive biomarker panels for ICI therapy.”1 However, this interpretation may be incorrect considering that not all POLE/POLD1 variants are oncogenic and therefore would not result in a high tumor mutation burden (TMB).
Rousseau B, Vidal J, Diaz LA. Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes. JAMA Oncol. 2020;6(4):589–590. doi:10.1001/jamaoncol.2020.0065
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.